Form 4: Atossa Therapeutics Director, Tessa Cigler, Acquires Stock Options
SEC Form 4 Filing
Director Tessa Cigler acquired stock options in Atossa Therapeutics, Inc. on March 9, 2024.
Summary
- On March 9, 2024, Tessa Cigler, a director of Atossa Therapeutics, Inc., acquired 20,834 stock options with an exercise price of $1.09.
- These options vest in four equal quarterly installments following March 9, 2024, contingent upon continued service.
- Following the transaction, Ms. Cigler directly owns 20,834 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The director's acquisition could be seen as a positive signal, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align the interests of management with those of shareholders.
Stakeholder Impact
- The stock option grant could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/09/2024 | Date of the transaction: Tessa Cigler acquired stock options. |
| 03/09/2024 | Vesting start date: Options vest in four equal quarterly installments following this date. |
| 03/09/2034 | Expiration date of the stock options. |
| 03/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.